Unless such surprises materialize, analysts like Phipps see the Dynavax story as largely written, with most of the remaining upside and downside bounded by Sanofi’s $15.50 per share offer. Inhibikase ...

The leading approach to the simplex method, a widely used technique for balancing complex logistical constraints, can’t get ...

Altimmune's pemvidutide shows strong Phase IIb results for MASH, promising Phase III prospects. Read here for more analysis ...